Published in J Clin Microbiol on February 01, 2005
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
The mycetoma knowledge gap: identification of research priorities. PLoS Negl Trop Dis (2014) 1.32
Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis (2007) 1.02
Molecular mycological diagnosis and correct antimycotic treatments. J Clin Microbiol (2005) 1.02
Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag (2006) 0.86
Hand Mycetoma: The Mycetoma Research Centre Experience and Literature Review. PLoS Negl Trop Dis (2016) 0.79
Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review. Medicine (Baltimore) (2015) 0.79
Scedosporiosis in a Combined Kidney and Liver Transplant Recipient: A Case Report of Possible Transmission from a Near-Drowning Donor. Case Rep Transplant (2016) 0.75
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Voriconazole: a new triazole antifungal agent. Clin Infect Dis (2003) 3.19
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother (1999) 2.74
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol (2001) 2.13
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J (2002) 1.97
Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis (2000) 1.81
Amphotericin B: spectrum and resistance. J Antimicrob Chemother (2002) 1.77
Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol (1998) 1.63
Antifungal activity of the new azole UK-109, 496 (voriconazole). Mycoses (1999) 1.60
Cutaneous infection due to Scedosporium apiospermum in an immunosuppressed patient. J Eur Acad Dermatol Venereol (2003) 1.57
The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses (1990) 1.53
Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis (2000) 1.23
Scedosporium species infections and treatments. J Chemother (2003) 1.23
Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother (2003) 1.16
Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol (2003) 1.15
Primary cutaneous fungal infections in solid organ transplantation: a case series. Am J Transplant (2002) 1.05
Scedosporium apiospermum skin infection: a case report and review of the literature. J Am Acad Dermatol (1998) 1.04
Cutaneous Scedosporium apiospermum infection in an immunocompromised patient. J Clin Pathol (1999) 0.97
Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: a case of mistaken identity. J Heart Lung Transplant (1998) 0.96
Lymphocutaneous infection due to Scedosporium apiospermum. Int J Dermatol (1997) 0.94
Localized skin infection due to Scedosporium apiospermum: report of two cases. Br J Dermatol (1999) 0.94
Acute pyogenic Pseudallescheria boydii foot infection sequentially treated with miconazole and itraconazole. J Infect (1992) 0.93
Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation (2003) 0.91
Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukaemia. J Clin Pathol (1996) 0.88
Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Arch Dermatol (1996) 0.87
Subcutaneous scedosporiosis. Report of two cases and review of the literature. Rev Inst Med Trop Sao Paulo (1998) 0.85
Successful treatment due to vacuum seal technique of a severe Scedosporium apiospermum skin infection in a renal transplant recipient. Nephrol Dial Transplant (2004) 0.84
Subcutaneous pseudallescheriasis in a renal transplant recipient. Mycopathologia (1994) 0.84
Scedosporium apiospermum infection imitating lymphocutaneous sporotrichosis in a patient with myeloblastic-monocytic leukaemia. Br J Dermatol (1995) 0.84
Cutaneous infection by Scedosporium apiospermum and its successful treatment with itraconazole. Clin Exp Dermatol (1997) 0.84
Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect (2003) 0.83
Scedosporium apiospermum skin infection in a patient with nephrotic syndrome. Acta Derm Venereol (1997) 0.83
Disseminated infection due to Scedosporium apiospermum in a patient with acute myelogenous leukemia. Leuk Lymphoma (2003) 0.82
Case report. Atypical cutaneous pseudallescheriosis refractory to antifungal agents. Mycoses (1999) 0.82
Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med Pediatr Oncol (2003) 0.81
Skin infection caused by Scedosporium apiospermum. Mycoses (2003) 0.79
Pseudallescheriasis as an aggressive opportunistic infection in a bone marrow transplant recipient. Arch Pathol Lab Med (2002) 0.78
Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol (2001) 0.78
Cutaneous infection with Scedosporium apiospermum in a patient treated with corticosteroids. Acta Derm Venereol (1999) 0.77
Lymphocutaneous syndrome due to Scedosporium apiospermum. Clin Microbiol Infect (2001) 0.77
Pseudoallescheria boydii soft tissue abscess. Clin Orthop Relat Res (1987) 0.77
Post-craniotomy wound infection caused by Pseudallescheria boydii. Case report. J Neurosurg (1986) 0.77
Nodular lymphangitis: clinical features, differential diagnosis and management. Curr Clin Top Infect Dis (1994) 0.76
Development of the human infant intestinal microbiota. PLoS Biol (2007) 18.91
Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis (2005) 9.23
CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med (2006) 5.89
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother (2002) 2.89
TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol (2005) 2.77
Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis (2002) 2.70
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis (2003) 2.62
Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis (2003) 2.45
Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol (2009) 2.44
Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc Natl Acad Sci U S A (2006) 2.34
Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis (2009) 2.20
Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol (2008) 2.16
Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol (2007) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med (2002) 1.89
Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol (2004) 1.86
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci U S A (2010) 1.82
Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother (2003) 1.77
Lymphoid interstitial pneumonia: a narrative review. Chest (2002) 1.70
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2002) 1.65
Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation (2003) 1.63
Zygomycosis. Infect Dis Clin North Am (2002) 1.58
The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis (2004) 1.58
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) (2002) 1.53
Molecular assessment of surgical-resection margins of gastric cancer by mass-spectrometric imaging. Proc Natl Acad Sci U S A (2014) 1.53
Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution. Am J Clin Pathol (2009) 1.52
Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol (2010) 1.51
Imaging for suspected appendicitis: negative appendectomy and perforation rates. Radiology (2002) 1.50
Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol (2011) 1.50
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.47
Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother (2008) 1.47
Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol (2004) 1.43
A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol (2003) 1.42
Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev Iberoam Micol (2010) 1.40
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2008) 1.36
Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw (2012) 1.35
Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant (2011) 1.32
Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood (2006) 1.31
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses (2007) 1.27
Dual in vivo magnetic resonance evaluation of magnetically labeled mouse embryonic stem cells and cardiac function at 1.5 t. Magn Reson Med (2006) 1.25
Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J (2011) 1.25
Taxonomy and phylogeny of the Fusarium dimerum species group. Mycologia (2009) 1.24
Novel multilocus sequence typing scheme reveals high genetic diversity of human pathogenic members of the Fusarium incarnatum-F. equiseti and F. chlamydosporum species complexes within the United States. J Clin Microbiol (2009) 1.22
miR-29b participates in early aneurysm development in Marfan syndrome. Circ Res (2011) 1.22
Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr (2002) 1.22
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother (2002) 1.20
Susceptibility testing and clinical outcome in fungal keratitis. Br J Ophthalmol (2010) 1.18
Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment. Expert Rev Anti Infect Ther (2012) 1.15
Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol (2009) 1.14
Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol (2002) 1.14
Use of a single serum sample for diagnosis of acute toxoplasmosis in pregnant women and other adults. J Clin Microbiol (2005) 1.13
Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs. J Clin Microbiol (2013) 1.11
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol (2005) 1.11
The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail (2002) 1.09
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.07
Primary cardiac angiosarcoma: case report and review of the literature. Cardiovasc Pathol (2006) 1.06
Two new species of Mucor from clinical samples. Med Mycol (2010) 1.05
Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother (2009) 1.05
Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood (2006) 1.05
Identification of tyrosine kinases overexpressed in head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 1.04
Multicenter evaluation of the new VITEK 2 advanced colorimetric yeast identification card. J Clin Microbiol (2007) 1.03
Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis (2007) 1.02
Endothelial fate mapping in mice with pulmonary hypertension. Circulation (2013) 1.02
Molecular mycological diagnosis and correct antimycotic treatments. J Clin Microbiol (2005) 1.02
Gastric pacing for severe gastroparesis in a heart-lung transplant recipient. J Heart Lung Transplant (2004) 1.01
Diagnostic approach to ocular toxoplasmosis. Ocul Immunol Inflamm (2011) 1.00
Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun (2004) 1.00
Emboli capture using the Embol-X intraaortic filter in cardiac surgery: a multicentered randomized trial of 1,289 patients. Ann Thorac Surg (2003) 1.00
Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother (2005) 0.98
In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother (2003) 0.98
Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant (2009) 0.97
Paecilomyces lilacinus vaginitis in an immuno-competent patient. Emerg Infect Dis (2003) 0.97
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis (2007) 0.96
Ablation of mitral annular and leaflet muscle: effects on annular and leaflet dynamics. Am J Physiol Heart Circ Physiol (2003) 0.96
Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology. J Transl Med (2013) 0.96
Recurrent lymphoma of the lung: computed tomography appearance. J Comput Assist Tomogr (2005) 0.96